共 50 条
- [41] Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2/3 trialJOURNAL OF DERMATOLOGY, 2012, 39 (09): : 761 - 769Nakagawa, HidemiSchenkel, BradKato, MaiKato, TakeshiIgarashi, Atsuyuki
- [42] Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: Results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitisJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB86 - AB86Paller, AmyTom, WynnisLebwohl, Mark M.Blumenthal, Robin L.Boguniewicz, MarkEichenfield, Lawrence S.Forsha, Douglass W.Simpson, Eric L.Gold, Linda SteinZaenglein, Andrea L.Call, R. S.Rees, W. C.Zane, L. T.Hebert, A. A.
- [43] Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trialJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (07) : 1543 - 1552Wollenberg, A.Nakahara, T.Maari, C.Peris, K.Lio, P.Augustin, M.Silverberg, J. I.Rueda, M. J.DeLozier, A. M.Pierce, E.Yang, F. E.Sun, L.Ball, S.Tauber, M.Paul, C.
- [44] Safety of ATI-502, a novel topical JAK1/3 inhibitor, in adults with moderate to severe atopic dermatitis: Results from a phase 2a open-label trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB170 - AB170Smith, StacyBhatia, NealShanler, Stuart D.DeMoor, RebeccaSchnyder, Judith
- [45] Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO TrialINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (04): : 823 - 833Wortel, Ruud C.Oomen-de Hoop, EstherHeemsbergen, Wilma D.Pos, Floris J.Incrocci, Luca
- [46] Health-Related Quality Of Life (hrqol) In Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Sun-101 (glycopyrrolate/eflow®): Findings From The Phase 3 Golden StudiesAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195Ferguson, G. T.Kerwin, E. M.Donohue, J. F.Ozol-Godfrey, A.Ganapathy, V.
- [47] Sustained improvement in general health-related quality life and work productivity in patients with moderate to severe psoriasis treated with guselkumab: 3-year data from clinical trial VOYAGE 2JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB280 - AB280Reich, K.Gordon, K. B.Foley, P.Lomaga, M.Han, C.Song, M.Shen, Y. -K.Radtke, M. A.Wu, J. J.Armstrong, A.
- [48] Dupilumab improves health related quality of life in uncontrolled, moderate-to-severe asthma patients with comorbid allergic rhinitis from the phase 3 LIBERTY ASTHMA QUEST studyALLERGY, 2018, 73 : 30 - 31Maspero, J.Busse, W. W.Katelaris, C. H.Yanez, A.Guillonneau, S.Chen, Z.Staudinger, H.Chao, J.Amin, N.Pirozzi, G.Ruddy, M.Akinlade, B.Graham, N. M. H.Teper, A.Khan, A.
- [49] Late Breaking Abstract-RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD studyEUROPEAN RESPIRATORY JOURNAL, 2018, 52Maurer, BrianSingh, DaveMartinez, FernandoNewman, Kenneth
- [50] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe psoriasis: Findings from the phase 3 POETYK PSO-3 and PSO-4 trialsAUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 28 - 29Foley, PeterZhang, JianzhongImafuku, ShinichiDing, YangfengOkubo, YukariLi, HuiTada, YayoiLi, LinfengOhtsuki, MamitaroPan, WeiliLu, YanHao, ChengXian, JiangHo, Ji-ChenGuo, ShupingSeo, Seong JunNapoli, AndrewChatterjee, ArkenduKisa, Renata M.Banerjee, SubhashisMorita, Akimichi